Aventis/Regeneron VEGF Colorectal Cancer Indication Part Of $500 Mil. Deal
Aventis and Regeneron are pursuing a colorectal indication for Regeneron's vascular endothelial growth factor trap after seeing positive results from Genentech's Phase III VEGF inhibitor Avastin
You may also be interested in...
The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco
Genentech believes that its investigational agent Avastin will become standard add-on therapy to chemotherapy in the treatment of colorectal cancer after unveiling data demonstrating that the VEGF inhibitor "markedly" improves survival in first-line metastatic disease
Regeneron will explore ways to fine-tune its investigational obesity agent Axokine to increase the percentage of patients that do not develop antibodies to the protein, CEO Leonard Schleifer, MD/PhD, said